Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Everolimus does not improve survival in advance hepatocellular carcinoma

This week's issue of the Journal of the Amercian Medical Association examines the effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib.

News image

Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma.

Dr Andrew Zhu and colleagues assessed the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed.

EVOLVE-1 was a randomized, double-blind, phase 3 study conducted among 546 adults with Barcelona Clinic Liver Cancer stage B or C hepatocellular carcinoma and Child-Pugh A liver function whose disease progressed during or after sorafenib or who were intolerant of sorafenib.

The team enrolled patients from 17 countries between 2010 and 2012.

Randomization was stratified by region and macrovascular invasion.

Hepatitis B viral reactivation was experienced by 39 patients
Journal of the American Medical Association

Everolimus, 7.5 mg/d, or matching placebo, both given in combination with best supportive care and continued until disease progression or intolerable toxicity.

Per the 2:1 randomization scheme, 362 patients were randomized to the everolimus group and 184 patients to the placebo group.

The team's primary end point was overall survival.

The research team's secondary end points included time to progression and the disease control rate.

The team noted no significant difference in overall survival between treatment groups, with 84% of deaths in the everolimus group, and 82% of deaths in the placebo group.

Median time to progression with everolimus and placebo was 3 months, and 2.6 months, respectively.

The team found that disease control rate was 56% and 45%, respectively.

The researchers noted that the most common grade 3/4 adverse events for everolimus vs placebo were anemia, asthenia, and decreased appetite.

No patients experienced hepatitis C viral flare.

Based on central laboratory results, hepatitis B viral reactivation was experienced by 39 patients.

All cases were asymptomatic, but 3 everolimus recipients discontinued therapy.

Dr Zhu's team concludes, "Everolimus did not improve overall survival in patients with advanced hepatocellular carcinoma whose disease progressed during or after receiving sorafenib or who were intolerant of sorafenib."

JAMA 2014;312(1):57-67
07 July 2014

Go to top of page Email this page Email this page to a colleague

 27 November 2014

Advanced search
 27 November 2014 
Prediction of functional GI disorders later in life
 27 November 2014 
Differences in the incidence of esophageal adenocarcinoma
 27 November 2014 
End points of outcomes in primary biliary cirrhosis
 26 November 2014 
Detection of gastric precancerous conditions
 26 November 2014 
Vegetables and garlic and colorectal cancer risk
 26 November 2014 
Fertility in women with celiac disease
 25 November 2014 
Esophagogastric junction of children with GERD
 25 November 2014 
Symptom activity index for eosinophilic esophagitis
 25 November 2014 
Placebo response rate in fistulizing Crohn's
 24 November 2014 
Nasoenteric tube feeding in acute pancreatitis
 24 November 2014 
Corticosteroids and infections in elderly-onset IBD
 24 November 2014 
Adhesions in abdominal and pelvic surgery
 21 November 2014 
Hepatic involvement in IgG4-related disease
 21 November 2014 
Skin cancer in ulcerative colitis patients
 21 November 2014 
Mortality of chemoembolization in hepatocellular carcinoma
 20 November 2014 
Global measures in chronic idiopathic constipation
 20 November 2014 
Macrophage activation in alcoholic hepatitis
 20 November 2014 
Covert hepatic encephalopathy and survival
 19 November 2014 
Thiopurine withdrawal in IBD
 19 November 2014 
Esophageal narrowing in esophageal eosinophilia
 19 November 2014 
Second intestinal resection in Crohn's
 18 November 2014 
Colorectal neoplasia and vitamin D
 18 November 2014 
Food-associated changes in the intestinal mucosa in IBS
 18 November 2014 
Alternative medicine use by US adults
 17 November 2014 
Allergy-related diseases and abdominal pain in childhood
 17 November 2014 
Treatment of obesity in primary care settings
 17 November 2014 
Diagnosis of monogenic very early onset IBD
 14 November 2014 
Second intestinal resection in Crohn's
 14 November 2014 
HCC risk in active stage Hep B
 14 November 2014 
Thiopurine and clinical remission in IBD
 13 November 2014 
Antibiotics and risk of new-onset Crohn’s
 13 November 2014 
Chronic Hep C genotype 1 treatment after relapse
 13 November 2014 
Chemoembolization for hepatocellular carcinoma
 12 November 2014 
Risk of hepatocellular carcinoma
 12 November 2014 
Abdominal symptom severity in chronic idiopathic constipation
 12 November 2014 
Screening colonoscopy
 11 November 2014 
Hepatocellular carcinoma in Hep B with nucleotide analogue
 11 November 2014 
Familial colorectal cancer screening
 11 November 2014 
Fecal microbiota transplant for C. diff
 10 November 2014 
STaples IPAA for ulcerative colitis
 10 November 2014 
Blood stream infections in acute liver failure
 10 November 2014 
Ig4-related disease
 07 November 2014 
Host and viral factors in chronic Hep C
 07 November 2014 
Celiac diagnosis without biopsy
 07 November 2014 
Pricing practices of gastroenterologists
 06 November 2014 

Colorectal surgery postdischarge occurrences and readmissions

 06 November 2014 
Thromboprophylaxis in IBD
 06 November 2014 
Steatosis biomarkers in NAFLD
 05 November 2014 
Readmission risk factors for patients with IBD
 05 November 2014 
Hysterectomy and colonoscopy completion
 05 November 2014 
Adalimumab in Crohn's disease
 04 November 2014 
Gut barrier dysfunction and CNS disorders
 04 November 2014 
Hemospray for nonvariceal upper GI bleeding
 04 November 2014 
Sleep duration and ulcerative colitis
 03 November 2014 
Mucosal pathophysiology in HIV and IBD
 03 November 2014 
Managing bleeding gastroduodenal ulcers
 03 November 2014 
Identifying inflammation in ulcerative colitis
 31 October 2014 
Pregnancy complications in celiac disease
 31 October 2014 
Pediatric NAFLD
 31 October 2014 
C. difficile infection with metronidazole

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us